A detailed history of Vanguard Group Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,556,699 shares of CCCC stock, worth $20.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,556,699
Previous 2,920,028 21.8%
Holding current value
$20.9 Million
Previous $23.9 Million 31.12%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.05 - $8.1 $2.58 Million - $5.16 Million
636,671 Added 21.8%
3,556,699 $16.4 Million
Q1 2024

May 10, 2024

BUY
$5.3 - $11.0 $4.88 Million - $10.1 Million
920,627 Added 46.05%
2,920,028 $23.9 Million
Q4 2023

Feb 14, 2024

BUY
$1.18 - $6.03 $87,963 - $449,506
74,545 Added 3.87%
1,999,401 $11.3 Million
Q3 2023

Nov 14, 2023

BUY
$1.81 - $3.89 $44,345 - $95,305
24,500 Added 1.29%
1,924,856 $3.58 Million
Q2 2023

Aug 14, 2023

SELL
$2.75 - $3.77 $583,467 - $799,880
-212,170 Reduced 10.04%
1,900,356 $5.23 Million
Q1 2023

May 15, 2023

BUY
$3.1 - $9.02 $147,594 - $429,451
47,611 Added 2.31%
2,112,526 $6.63 Million
Q4 2022

Feb 10, 2023

BUY
$5.42 - $10.24 $245,314 - $463,472
45,261 Added 2.24%
2,064,915 $12.2 Million
Q3 2022

Nov 14, 2022

BUY
$8.03 - $12.77 $473,296 - $752,676
58,941 Added 3.01%
2,019,654 $17.7 Million
Q2 2022

Aug 12, 2022

SELL
$5.06 - $26.46 $310,830 - $1.63 Million
-61,429 Reduced 3.04%
1,960,713 $14.8 Million
Q1 2022

May 13, 2022

BUY
$19.99 - $33.23 $113,603 - $188,846
5,683 Added 0.28%
2,022,142 $49.1 Million
Q4 2021

Feb 14, 2022

BUY
$29.39 - $46.86 $2.29 Million - $3.65 Million
77,884 Added 4.02%
2,016,459 $64.9 Million
Q3 2021

Nov 12, 2021

BUY
$35.91 - $50.5 $19.1 Million - $26.9 Million
531,735 Added 37.8%
1,938,575 $86.6 Million
Q2 2021

Aug 13, 2021

BUY
$30.39 - $42.18 $42.8 Million - $59.3 Million
1,406,840 New
1,406,840 $53.2 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $288M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.